Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung Cancer: A Systematic Review

Author(s): Pablo Redruello-Guerrero, Paula Córdoba-Peláez, Antonio Jesús Láinez-Ramos-Bossini, Mario Rivera-Izquierdo, Cristina Mesas, Raul Ortiz*, Jose Prados* and Gloria Perazzoli

Volume 21, Issue 10, 2024

Published on: 07 March, 2024

Page: [1346 - 1361] Pages: 16

DOI: 10.2174/0115672018272162231116093143

Price: $65

conference banner
Abstract

Background: Liposomal Doxorubicin (Doxil®) was one of the first nanoformulations approved for the treatment of solid tumors. Although there is already extensive experience in its use for different tumors, there is currently no grouped evidence of its therapeutic benefits in non-small cell lung cancer (NSCLC). A systematic review of the literature was performed on the therapeutic effectiveness and benefits of Liposomal Doxil® in NSCLC.

Methods: A total of 1022 articles were identified in publications up to 2020 (MEDLINE, Cochrane, Web of Science Core Collection and Scopus). After applying inclusion criteria, the number was restricted to 114, of which 48 assays, including in vitro (n=20) and in vivo (animals, n=35 and humans, n=6) studies, were selected.

Results: The maximum inhibitory concentration (IC50), tumor growth inhibition rate, response and survival rates were the main indices for evaluating the efficacy and effectiveness of Liposomal DOX. These have shown clear benefits both in vitro and in vivo, improving the IC50 of free DOX or untargeted liposomes, depending on their size, administration, or targeting.

Conclusion: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC, additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on its activity and effects in humans.

Keywords: Doxil®, non-small lung cancer, caelyx, myocet, in vivo assay, clinical trial, systematic review.

« Previous Next »
Graphical Abstract

[1]
Cancer Today Available from: https://gco.iarc.fr/today/home
[2]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[3]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin., 2019, 69(1), 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[4]
García-Navarro, C.; Marrades, R.M.; López-Rodó, L. Tumores broncopulmonares. Medicina Interna, 19th ed; Elservier: Barcelona, 2020, pp. 735-745.
[5]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61(2), 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[6]
Gibbons, D.L.; Byers, L.A.; Kurie, J.M. Smoking, p53 mutation, and lung cancer. Mol. Cancer Res., 2014, 12(1), 3-13.
[http://dx.doi.org/10.1158/1541-7786.MCR-13-0539] [PMID: 24442106]
[7]
Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature, 2018, 553(7689), 446-454.
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]
[8]
Rauma, V.; Andersson, S.; Robinson, E.M.; Räsänen, J.V.; Sintonen, H.; Salo, J.A.; Ilonen, I.K. Thoracotomy and VATS surgery in local non–small-cell lung cancer: Differences in long-term health-related quality of life. Clin. Lung Cancer, 2019, 20(5), 378-383.
[http://dx.doi.org/10.1016/j.cllc.2019.05.010] [PMID: 31202692]
[9]
Ortiz, R.; Cabeza, L.; Perazzoli, G.; Jimenez-Lopez, J.; García-Pinel, B.; Melguizo, C.; Prados, J. Nanoformulations for glioblastoma multiforme: A new hope for treatment. Future Med. Chem., 2019, 11(18), 2461-2482.
[http://dx.doi.org/10.4155/fmc-2018-0521] [PMID: 31544490]
[10]
Redruello, P.; Perazzoli, G.; Cepero, A.; Quiñonero, F.; Mesas, C.; Doello, K.; Láinez-Ramos-Bossini, A.; Rivera-Izquierdo, M.; Melguizo, C.; Prados, J. Nanomedicine in pancreatic cancer: A new hope for treatment. Curr. Drug Targets, 2020, 21(15), 1580-1592.
[http://dx.doi.org/10.2174/1389450121666200703195229] [PMID: 32619168]
[11]
Cryer, A.M.; Thorley, A.J. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol. Ther., 2019, 198, 189-205.
[http://dx.doi.org/10.1016/j.pharmthera.2019.02.010] [PMID: 30796927]
[12]
Paz-Ares, L.; Ross, H.; O’Brien, M.; Riviere, A.; Gatzemeier, U.; Von Pawel, J.; Kaukel, E.; Freitag, L.; Digel, W.; Bischoff, H.; García-Campelo, R.; Iannotti, N.; Reiterer, P.; Bover, I.; Prendiville, J.; Eisenfeld, A.J.; Oldham, F.B.; Bandstra, B.; Singer, J.W.; Bonomi, P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer, 2008, 98(10), 1608-1613.
[http://dx.doi.org/10.1038/sj.bjc.6604372] [PMID: 18475293]
[13]
Boulikas, T. Clinical overview on lipoplatin ™: A successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs, 2009, 18(8), 1197-1218.
[http://dx.doi.org/10.1517/13543780903114168] [PMID: 19604121]
[14]
Von Hoff, D.D.; Mita, M.M.; Ramanathan, R.K.; Weiss, G.J.; Mita, A.C.; LoRusso, P.M.; Burris, H.A., III; Hart, L.L.; Low, S.C.; Parsons, D.M.; Zale, S.E.; Summa, J.M.; Youssoufian, H.; Sachdev, J.C.; Phase, I. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res., 2016, 22(13), 3157-3163.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2548] [PMID: 26847057]
[15]
Svenson, S.; Wolfgang, M.; Hwang, J.; Ryan, J.; Eliasof, S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J. Control. Release, 2011, 153(1), 49-55.
[http://dx.doi.org/10.1016/j.jconrel.2011.03.007] [PMID: 21406204]
[16]
Diaferia, C.; Rosa, E.; Accardo, A.; Morelli, G. Peptide‐based hydrogels as delivery systems for doxorubicin. J. Pept. Sci., 2022, 28(1), e3301.
[http://dx.doi.org/10.1002/psc.3301] [PMID: 33491262]
[17]
Johansen, P.B.; Jensen, S.E.; Rasmussen, S.N.; Dalmark, M. Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine. Cancer Chemother. Pharmacol., 1984, 13(1), 5-8.
[http://dx.doi.org/10.1007/BF00401437] [PMID: 6329539]
[18]
Waterhouse, D.N.; Tardi, P.G.; Mayer, L.D.; Bally, M.B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf., 2001, 24(12), 903-920.
[http://dx.doi.org/10.2165/00002018-200124120-00004] [PMID: 11735647]
[19]
Forssen, E.A. Tőkés, Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun., 1979, 91(4), 1295-1301.
[http://dx.doi.org/10.1016/0006-291X(79)91207-5] [PMID: 526304]
[20]
Rahman, A.; Kessler, A.; More, N.; Sikic, B.; Rowden, G.; Woolley, P.; Schein, P.S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res., 1980, 40(5), 1532-1537.
[PMID: 7370991]
[21]
Cesarman, E.; Damania, B.; Krown, S.E.; Martin, J.; Bower, M.; Whitby, D. Kaposi sarcoma. Nat. Rev. Dis. Primers, 2019, 5(1), 9.
[http://dx.doi.org/10.1038/s41572-019-0060-9] [PMID: 30705286]
[22]
Gordon, A.N.; Fleagle, J.T.; Guthrie, D.; Parkin, D.E.; Gore, M.E.; Lacave, A.J. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 2001, 19(14), 3312-3322.
[http://dx.doi.org/10.1200/JCO.2001.19.14.3312] [PMID: 11454878]
[23]
Sandro, P.; Carmela, P.; Marilena, D.N.; Sabrina, C.C.; Chiara, C.; Rosa, T.; Laura, A. Treatment of recurrent epithelial ovarian cancer. Cancer, 2019, 125(S24), 4609-4615.
[24]
Shafei, A.; El-Bakly, W.; Sobhy, A.; Wagdy, O.; Reda, A.; Aboelenin, O.; Marzouk, A.; El Habak, K.; Mostafa, R.; Ali, M.A.; Ellithy, M. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed. Pharmacother., 2017, 95, 1209-1218.
[http://dx.doi.org/10.1016/j.biopha.2017.09.059] [PMID: 28931213]
[25]
Usmani, S.Z.; Lonial, S. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk., 2014, 14, S71-S77.
[http://dx.doi.org/10.1016/j.clml.2014.06.016] [PMID: 25486960]
[26]
Barenholz, Y.C. Doxil® — The first FDA-approved nano-drug: Lessons learned. J. Control. Release, 2012, 160(2), 117-134.
[http://dx.doi.org/10.1016/j.jconrel.2012.03.020] [PMID: 22484195]
[27]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J. Clin. Epidemiol., 2009, 62(10), e1-e34.
[http://dx.doi.org/10.1016/j.jclinepi.2009.06.006] [PMID: 19631507]
[28]
Beyer, U.; Rothen-Rutishauser, B.; Unger, C.; Wunderli-Allenspach, H.; Kratz, F. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy. Pharm. Res., 2001, 18(1), 29-38.
[http://dx.doi.org/10.1023/A:1011018525121] [PMID: 11336350]
[29]
Biswas, S.; Deshpande, P.P.; Perche, F.; Dodwadkar, N.S.; Sane, S.D.; Torchilin, V.P. Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer. Cancer Lett., 2013, 335(1), 191-200.
[http://dx.doi.org/10.1016/j.canlet.2013.02.020] [PMID: 23419527]
[30]
Chen, J.L.Y.; Pan, C.K.; Lin, Y.L.; Tsai, C.Y.; Huang, Y.S.; Yang, W.C.; Hsu, F.M.; Kuo, S.H.; Shieh, M.J. Preclinical evaluation of PEGylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer. Strahlenther. Onkol., 2021, 197(12), 1131-1142.
[http://dx.doi.org/10.1007/s00066-021-01835-9] [PMID: 34476531]
[31]
Chi, Y.; Yin, X.; Sun, K.; Feng, S.; Liu, J.; Chen, D.; Guo, C.; Wu, Z. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J. Control. Release, 2017, 261, 113-125.
[http://dx.doi.org/10.1016/j.jconrel.2017.06.027] [PMID: 28666726]
[32]
Ghosh, S.; Lalani, R.; Maiti, K.; Banerjee, S.; Patel, V.; Bhowmick, S.; Misra, A. Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer. Nanomedicine, 2020, 15(26), 2585-2607.
[http://dx.doi.org/10.2217/nnm-2020-0169] [PMID: 33090073]
[33]
Ghosh, S.; Lalani, R.; Maiti, K.; Banerjee, S.; Bhatt, H.; Bobde, Y.S.; Patel, V.; Biswas, S.; Bhowmick, S.; Misra, A. Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. Nanomedicine, 2021, 31, 102320.
[http://dx.doi.org/10.1016/j.nano.2020.102320] [PMID: 33075540]
[34]
Gray, B.P.; McGuire, M.J.; Brown, K.C. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One, 2013, 8(8), e72938.
[http://dx.doi.org/10.1371/journal.pone.0072938] [PMID: 24009717]
[35]
Gross, A.L.; Gillespie, J.W.; Petrenko, V.A. Promiscuous tumor targeting phage proteins. Protein Eng. Des. Sel., 2016, 29(3), 93-103.
[http://dx.doi.org/10.1093/protein/gzv064] [PMID: 26764410]
[36]
Hattori, Y.; Shibuya, K.; Kojima, K.; Miatmoko, A.; Kawano, K.; Ozaki, K.I.; Yonemochi, E. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin. Int. J. Oncol., 2015, 47(1), 211-219.
[http://dx.doi.org/10.3892/ijo.2015.2991] [PMID: 25955490]
[37]
He, X.; Na, M.H.; Kim, J.S.; Lee, G.Y.; Park, J.Y.; Hoffman, A.S.; Nam, J.O.; Han, S.E.; Sim, G.Y.; Oh, Y.K.; Kim, I.S.; Lee, B.H. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol. Pharm., 2011, 8(2), 430-438.
[http://dx.doi.org/10.1021/mp100266g] [PMID: 21222482]
[38]
Kuo, P.H.; Teng, Y.H.; Cin, A.L.; Han, W.; Huang, P.W.; Wang, L.H.C.; Chou, Y.T.; Yang, J.L.; Tseng, Y.L.; Kao, M.; Chang, M.D.T. Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. Drug Deliv., 2020, 27(1), 542-555.
[http://dx.doi.org/10.1080/10717544.2020.1745326] [PMID: 32241176]
[39]
Meghani, N.M.; Amin, H.H.; Park, C.; Park, J.B.; Cui, J.H.; Cao, Q.R.; Lee, B.J. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy. Int. J. Pharm., 2018, 545(1-2), 101-112.
[http://dx.doi.org/10.1016/j.ijpharm.2018.04.047] [PMID: 29698822]
[40]
Miatmoko, A.; Kawano, K.; Yoda, H.; Yonemochi, E.; Hattori, Y. Tumor delivery of liposomal doxorubicin prepared with poly- L -glutamic acid as a drug-trapping agent. J. Liposome Res., 2017, 27(2), 99-107.
[http://dx.doi.org/10.3109/08982104.2016.1166511] [PMID: 26982164]
[41]
Ogawara, K.; Un, K.; Minato, K.; Tanaka, K.; Higaki, K.; Kimura, T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. Int. J. Pharm., 2008, 359(1-2), 234-240.
[http://dx.doi.org/10.1016/j.ijpharm.2008.03.025] [PMID: 18448289]
[42]
Qiu, M.; Sun, H.; Meng, F.; Cheng, R.; Zhang, J.; Deng, C.; Zhong, Z. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo. J. Control. Release, 2018, 272, 107-113.
[http://dx.doi.org/10.1016/j.jconrel.2018.01.011] [PMID: 29355618]
[43]
Tagami, T.; Kubota, M.; Ozeki, T. Effective remote loading of doxorubicin into DPPC/Poloxamer 188 hybrid liposome to retain thermosensitive property and the assessment of carrier-based acute cytotoxicity for pulmonary administration. J. Pharm. Sci., 2015, 104(11), 3824-3832.
[http://dx.doi.org/10.1002/jps.24593] [PMID: 26228287]
[44]
Tagami, T.; Ando, Y.; Ozeki, T. Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A 2 for efficient pulmonary drug delivery to lung cancers. Int. J. Pharm., 2017, 517(1-2), 35-41.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.039] [PMID: 27865984]
[45]
Wang, Z.; Wen, J.; Liu, H.; Zheng, L.; Luo, H.; Liu, Z.; Chen, X.; Wang, F.; Li, D.; Pei, H.; Li, W.; Chen, L. Biodegradable interlayer-crosslinked polymer micelles with reduction sensitivity for non-small cell lung cancer therapy. J. Biomed. Nanotechnol., 2018, 14(7), 1225-1238.
[http://dx.doi.org/10.1166/jbn.2018.2538] [PMID: 29944097]
[46]
Yamada, A.; Taniguchi, Y.; Kawano, K.; Honda, T.; Hattori, Y.; Maitani, Y. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res., 2008, 14(24), 8161-8168.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0159] [PMID: 19088031]
[47]
Zou, Y.; Meng, F.; Deng, C.; Zhong, Z. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx? J. Control. Release, 2016, 239, 149-158.
[http://dx.doi.org/10.1016/j.jconrel.2016.08.022] [PMID: 27569664]
[48]
Foster, K.A.; Oster, C.G.; Mayer, M.M.; Avery, M.L.; Audus, K.L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp. Cell Res., 1998, 243(2), 359-366.
[http://dx.doi.org/10.1006/excr.1998.4172] [PMID: 9743595]
[49]
Steel, G.G.; Adams, K. Stem-cell survival and tumor control in the Lewis lung carcinoma. Cancer Res., 1975, 35(6), 1530-1535.
[PMID: 1169108]
[50]
Ben-Yosef, R.; Gipps, M.; Zeira, M. Hyperthermia and liposomal encapsulated doxorubicin. Isr. Med. Assoc. J., 2003, 5(6), 407-409.
[PMID: 12841010]
[51]
Beyer, I.; Cao, H.; Persson, J.; Song, H.; Richter, M.; Feng, Q.; Yumul, R.; van Rensburg, R.; Li, Z.; Berenson, R.; Carter, D.; Roffler, S.; Drescher, C.; Lieber, A. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin. Cancer Res., 2012, 18(12), 3340-3351.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3213] [PMID: 22535153]
[52]
Cabanes, A.; Even-Chen, S.; Zimberoff, J.; Barenholz, Y.; Kedar, E.; Gabizon, A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin. Cancer Res., 1999, 5(3), 687-693.
[PMID: 10100723]
[53]
Dicheva, B.M.; Seynhaeve, A.L.B.; Soulie, T.; Eggermont, A.M.M.; ten Hagen, T.L.M.; Koning, G.A. Pharmacokinetics, tissue distribution and therapeutic effect of cationic thermosensitive liposomal doxorubicin upon mild hyperthermia. Pharm. Res., 2016, 33(3), 627-638.
[http://dx.doi.org/10.1007/s11095-015-1815-y] [PMID: 26518763]
[54]
ElBayoumi, T.A.; Torchilin, V.P. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm., 2009, 6(1), 246-254.
[http://dx.doi.org/10.1021/mp8001528] [PMID: 19049322]
[55]
Harasym, T.O.; Cullis, P.R.; Bally, M.B. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol., 1997, 40(4), 309-317.
[http://dx.doi.org/10.1007/s002800050662] [PMID: 9225948]
[56]
Hattori, Y.; Ubukata, H.; Kawano, K.; Maitani, Y. Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice. Int. J. Pharm., 2011, 403(1-2), 178-184.
[http://dx.doi.org/10.1016/j.ijpharm.2010.10.009] [PMID: 20934498]
[57]
Ishida, T.; Shiraga, E.; Kiwada, H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J. Control. Release, 2009, 134(3), 194-200.
[http://dx.doi.org/10.1016/j.jconrel.2008.11.019] [PMID: 19095022]
[58]
Kirtane, A.R.; Narayan, P.; Liu, G.; Panyam, J. Polymer-surfactant nanoparticles for improving oral bioavailability of doxorubicin. J. Pharm. Investig., 2017, 47(1), 65-73.
[http://dx.doi.org/10.1007/s40005-016-0293-5]
[59]
Kuo, H.K.; Chen, Y.H.; Wu, P.C.; Wu, Y.C.; Huang, F.; Kuo, C.W.; Lo, L.H.; Shiea, J. Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. Invest. Ophthalmol. Vis. Sci., 2012, 53(6), 3167-3174.
[http://dx.doi.org/10.1167/iovs.11-7972] [PMID: 22491400]
[60]
Lowery, A.; Onishko, H.; Hallahan, D.E.; Han, Z. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J. Control. Release, 2011, 150(1), 117-124.
[http://dx.doi.org/10.1016/j.jconrel.2010.11.006] [PMID: 21075152]
[61]
Motamarry, A.; Negussie, A.H.; Rossmann, C.; Small, J.; Wolfe, A.M.; Wood, B.J.; Haemmerich, D. Real-time fluorescence imaging for visualization and drug uptake prediction during drug delivery by thermosensitive liposomes. Int. J. Hyperthermia, 2019, 36(1), 816-825.
[http://dx.doi.org/10.1080/02656736.2019.1642521] [PMID: 31451077]
[62]
Nemtsova, E.R.; Tikhonova, E.G.; Bezborodova, O.A.; Pankratov, A.A.; Venediktova, J.B.; Korotkevich, E.I.; Kostryukova, L.V.; Tereshkina, J.A. Preclinical study of pharmacological properties of doxorubicin-NPh. Bull. Exp. Biol. Med., 2020, 169(6), 778-782.
[http://dx.doi.org/10.1007/s10517-020-04977-5] [PMID: 33123920]
[63]
Parr, M.J.; Masin, D.; Cullis, P.R.; Bally, M.B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther., 1997, 280(3), 1319-1327.
[PMID: 9067319]
[64]
Pastorino, F.; Di Paolo, D.; Piccardi, F.; Nico, B.; Ribatti, D.; Daga, A.; Baio, G.; Neumaier, C.E.; Brignole, C.; Loi, M.; Marimpietri, D.; Pagnan, G.; Cilli, M.; Lepekhin, E.A.; Garde, S.V.; Longhi, R.; Corti, A.; Allen, T.M.; Wu, J.J.; Ponzoni, M. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin. Cancer Res., 2008, 14(22), 7320-7329.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0804] [PMID: 19010847]
[65]
Tailor, T.D.; Hanna, G.; Yarmolenko, P.S.; Dreher, M.R.; Betof, A.S.; Nixon, A.B.; Spasojevic, I.; Dewhirst, M.W. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther., 2010, 9(6), 1798-1808.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0856] [PMID: 20515941]
[66]
Taniguchi, Y.; Kawano, K.; Minowa, T.; Sugino, T.; Shimojo, Y.; Maitani, Y. Enhanced antitumor efficacy of folate‐linked liposomal doxorubicin with TGF‐β type I receptor inhibitor. Cancer Sci., 2010, 101(10), 2207-2213.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01646.x] [PMID: 20608940]
[67]
Vlahovic, G.; Ponce, A.M.; Rabbani, Z.; Salahuddin, F.K.; Zgonjanin, L.; Spasojevic, I.; Vujaskovic, Z.; Dewhirst, M.W. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br. J. Cancer, 2007, 97(6), 735-740.
[http://dx.doi.org/10.1038/sj.bjc.6603941] [PMID: 17712313]
[68]
Wang, Y.; Gonzalez, M.; Cheng, C.; Haouala, A.; Krueger, T.; Peters, S.; Decosterd, L.A.; van den Bergh, H.; Perentes, J.Y.; Ris, H.B.; Letovanec, I.; Debefve, E. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers Surg. Med., 2012, 44(4), 318-324.
[http://dx.doi.org/10.1002/lsm.22013] [PMID: 22362489]
[69]
Yokoi, K.; Chan, D.; Kojic, M.; Milosevic, M.; Engler, D.; Matsunami, R.; Tanei, T.; Saito, Y.; Ferrari, M.; Ziemys, A. Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier. J. Control. Release, 2015, 217, 293-299.
[http://dx.doi.org/10.1016/j.jconrel.2015.09.044] [PMID: 26409121]
[70]
Zhang, X.G.; Miao, J.; Dai, Y.Q.; Du, Y.Z.; Yuan, H.; Hu, F.Q. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm., 2008, 361(1-2), 239-244.
[http://dx.doi.org/10.1016/j.ijpharm.2008.06.002] [PMID: 18586075]
[71]
Falchook, G.S.; Duvic, M.; Hong, D.S.; Wheler, J.; Naing, A.; Lim, J.; Kurzrock, R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother. Pharmacol., 2012, 69(5), 1117-1126.
[http://dx.doi.org/10.1007/s00280-011-1808-4] [PMID: 22205203]
[72]
Koukourakis, M.I.; Koukouraki, S.; Giatromanolaki, A.; Archimandritis, S.C.; Skarlatos, J.; Beroukas, K.; Bizakis, J.G.; Retalis, G.; Karkavitsas, N.; Helidonis, E.S. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol., 1999, 17(11), 3512-3521.
[http://dx.doi.org/10.1200/JCO.1999.17.11.3512] [PMID: 10550149]
[73]
Koukourakis, M.I.; Patlakas, G.; Froudarakis, M.E.; Kyrgias, G.; Skarlatos, J.; Abatzoglou, I.; Bougioukas, G.; Bouros, D. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma. Anticancer Res., 2007, 27(5B), 3625-3631.
[PMID: 17972527]
[74]
Numico, G.; Castiglione, F.; Granetto, C.; Garrone, O.; Mariani, G.; Costanzo, G.D.; Ciura, P.L.; Gasco, M.; Ostellino, O.; Porcile, G.; Merlano, M. Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: A pilot trial. Lung Cancer, 2002, 35(1), 59-64.
[http://dx.doi.org/10.1016/S0169-5002(01)00269-0] [PMID: 11750714]
[75]
Patlakas, G.; Bouros, D.; Tsantekidou-Pozova, S.; Koukourakis, M.I. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res., 2005, 25(2B), 1427-1431.
[PMID: 15865101]
[76]
Tsoutsou, P.G.; Froudarakis, M.E.; Bouros, D.; Koukourakis, M.I. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res., 2008, 28(2B), 1349-1354.
[PMID: 18505077]
[77]
Hubert, A.; Lyass, O.; Pode, D.; Gabizon, A. Doxil (Caelyx): An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs, 2000, 11(2), 123-127.
[http://dx.doi.org/10.1097/00001813-200002000-00009] [PMID: 10789595]
[78]
Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N.I.; Lotem, M.; Brufman, G.; Gabizon, A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 2000, 89(5), 1037-1047.
[http://dx.doi.org/10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z] [PMID: 10964334]

Rights & Permissions Print Cite
Article Metrics
37
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy